Goa-based Molbio Diagnostics Restricted, backed by Temasek and Motilal Oswal Non-public Fairness, has submitted draft paperwork to the Securities and Trade Board of India (SEBI) to lift capital by means of an preliminary public providing (IPO).
As per the draft pink herring prospectus (DRHP), the IPO will embody a recent difficulty of fairness shares value as much as ₹200 crore and an offer-for-sale (OFS) of as much as 1.25 crore shares by current traders.
The corporate intends to allocate ₹99.3 crore from the proceeds to determine infrastructure for a brand new Analysis and Growth centre, a Centre of Excellence, and related workplace services. Moreover, ₹73.5 crore might be used to buy plant and equipment for its manufacturing models in Goa and Visakhapatnam, with the rest earmarked for normal company functions.
Established in 2000, Molbio Diagnostics specialises in point-of-care molecular diagnostics for over 30 ailments, together with tuberculosis, COVID-19, HIV, HPV, and Hepatitis B & C. Its flagship ‘Truenat’ platform—a battery-operated, transportable PCR machine—can ship outcomes inside an hour, even in resource-limited environments, and is patented in additional than 100 international locations.
The corporate operates 5 manufacturing services: two in Goa, one in Visakhapatnam, and two in Bengaluru, producing units, take a look at kits, and radiology gear through its subsidiary, Prognosys Medical Methods. As of March 31, 2025, Molbio’s annual manufacturing capability stood at 3,600 units and three.9 crore Truenat take a look at kits. For FY25, it reported income of ₹1,020 crore, marking practically 22% year-on-year development, and a revenue after tax of ₹138.5 crore.
Kotak Mahindra Capital, IIFL Capital Companies, Jefferies India, and Motilal Oswal Funding Advisors are the book-running lead managers for the difficulty.
Disclaimer: This story is for academic functions solely. The views and suggestions above are these of particular person analysts or broking corporations, not Mint. We advise traders to examine with licensed consultants earlier than making any funding selections.
